Thyroid disorders induced by immune checkpoint inhibitors
Endocrine · 12.02.2024 · 85 (1) · 67-79
DOI: 10.1007/s12020-024-03718-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrine, online erschienen am 12.02.2024. Verfasst von Dimitra Karaviti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine Unit and Diabetes Center, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University…. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Thyroid Diseases. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) are a revolutionary class of drugs that powerfully contribute to cancer therapy by harnessing the immune system to fight malignancies. However, their successful use as anti-cancer drugs is accompanied by a wide spectrum of immune-related adverse effects (irAEs), including endocrinopathies. Among them, thyroid dysfunction stands out as one of the most common endocrinopathies induced by ICI therapy and surfaces as a prominent concern. Destructive thyroiditis is the pathophysiological basis shared by the most common patterns of thyrotoxicosis followed by hypothyroidism and isolated hypothyroidism. Diagnostic approach is guided by clinical manifestation, laboratory evaluation and imaging modalities. Treatment approaches range from the substitution of levothyroxine to the utilization of beta blockers, depending on the extent of thyroid dysfunction’s severity. While the medical community is dealing with the evolution and complexities of immunotherapy, recognizing and effectively managing ICI-induced thyroid dysfunction emerged as crucial for enhancing patient safety and achieving improved outcomes. The aim of this review is to navigate the significance of ICI-induced thyroid dysfunction unraveling the various patterns, underlying mechanisms, diagnostic approaches, and treatment strategies. It, also, highlights the impact of various factors such as cancer subtype, ICI dosage, age, and genetic susceptibility on the risk of experiencing dysfunction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endocrine Unit and Diabetes Center, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Endocrinology, Alexandra Hospital, Athens, Greece.
- Endocrine Unit and Diabetes Center, Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. s.a.paschou@gmail.com.
ORCID-Profile: Dimitra Karaviti, Eleni-Rafaela Kani, Eleftheria Karaviti, Eleni Gerontiti, Stavroula A Paschou
Zitieren
APA
Karaviti, D., Kani, E. R., Karaviti, E., Gerontiti, E., Michalopoulou, O., Stefanaki, K., Kazakou, P., Vasileiou, V., Psaltopoulou, T., & Paschou, S. A. (2024). Thyroid disorders induced by immune checkpoint inhibitors. Endocrine, 85(1), 67-79. https://doi.org/10.1007/s12020-024-03718-2
Vancouver
Karaviti D, Kani ER, Karaviti E, Gerontiti E, Michalopoulou O, Stefanaki K, et al. Thyroid disorders induced by immune checkpoint inhibitors. Endocrine. 2024;85(1):67-79. doi:10.1007/s12020-024-03718-2
BibTeX
@article{Karaviti2024,
author = {Karaviti, Dimitra and Kani, Eleni-Rafaela and Karaviti, Eleftheria and Gerontiti, Eleni and Michalopoulou, Olympia and Stefanaki, Katerina and Kazakou, Paraskevi and Vasileiou, Vasiliki and Psaltopoulou, Theodora and Paschou, Stavroula A},
title = {Thyroid disorders induced by immune checkpoint inhibitors},
journal = {Endocrine},
year = {2024},
volume = {85},
number = {1},
pages = {67--79},
doi = {10.1007/s12020-024-03718-2}
}
EUVIMED